|Day Low/High||2.33 / 2.80|
|52 Wk Low/High||2.63 / 18.56|
- Clinical trial targeting enrollment of approximately 300 anti-PD-1 refractory melanoma patients at approximately 80 global trial sites -
Investors considering a purchase of Idera Pharmaceuticals Inc stock, but cautious about paying the going market price of $1.99/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the August put at the $2 strike, which has a bid at the time of this writing of 35 cents.
Analysts see a year of robust deal action ahead due in part to clarity from a tax standpoint.
The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Idera Pharmaceuticals, Inc.
Company to Present at the 36th Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2018 at 11:00 AM PT/2:00 PM ET
Phase 3 Trial Initiation Planned for First Quarter 2018
The most recent short interest data has been released for the 10/31/2017 settlement date, which shows a 5,553,069 share decrease in total short interest for Idera Pharmaceuticals Inc , to 3,061,046, a decrease of 64.46% since 10/13/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
The most recent short interest data has been released for the 10/13/2017 settlement date, which shows a 1,345,734 share decrease in total short interest for Idera Pharmaceuticals Inc , to 8,614,115, a decrease of 13.51% since 09/29/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
Investors in Idera Pharmaceuticals Inc saw new options become available this week, for the May 2018 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 235 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
The New Haven, Conn.-based firm on Sept. 9 received a termination notice regarding its license and collaboration pact with Johnson & Johnson's Janssen Pharmaceuticals Inc. on hepatitis C.
Clinical Data from Ongoing Phase 1/2 Trial of IMO-2125 in anti-PD-1 Refractory Melanoma to be presented Sunday, September 10 at the European Society for Medical Oncology Congress (ESMO) in Madrid, Spain
IMO-2125 Clinical Trial Data Update at ESMO in September
IMO-2125 Advances to Phase 2 Clinical Trial in PD-1 Refractory Melanoma
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.